Leveraging RWD can lessen the strain normally put on investigators and sites.
How technology can maximize use of manufacturer copay and patient assistance programs.
Five emerging themes likely to impact pharma in the new year.
Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.
This application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).
Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.
New regulations set stage for updated ESG considerations.
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
On the back of COVID-19, pharma has an opportunity to radically rethink a long-held reluctance to build end-customer relationships into their core business models, writes Simon Bates and Valerie Phillips.
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.
New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
The industry holds the key to true change to the drug access landscape.
With the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.
Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.
COVID-19 pandemic sets new standards for life sciences industry.
Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT
Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
Substance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the use of long-acting injectables.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.